PD, PK, and Safety of ALTO-203 in Patients With MDD
Study sponsor: Alto Neuroscience
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2025-04-14Actual
Enrollment · participants69Actual
Source updated2026-04-17Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.